Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements

Clinical Pharmacology and Therapeutics
A C HookerS D Baker

Abstract

The relationship between cytochrome P4503A4 (CYP3A4) activity and docetaxel clearance in patients with varying degrees of liver function (LF) was evaluated. Docetaxel 40, 50, or 75 mg/m(2) was administered to 85 patients with advanced cancer; 23 of 77 evaluable patients had abnormalities in LF tests. Baseline CYP3A activity was assessed using the erythromycin breath test (ERMBT). Pharmacokinetic studies and toxicity assessments were performed during cycle 1 of therapy and population modeling was performed using NONMEM. Docetaxel unbound clearance was lower (317 vs. 470 l/h) and more variable in patients with LF abnormalities compared to patients with normal LF. Covariates evaluated accounted for 83% of variability on clearance in patients with liver dysfunction, with CYP3A4 activity accounting for 47% of variation; covariates accounted for only 23% of variability in patients with normal LF. The clinical utility of the ERMBT may lie in identifying safe docetaxel doses for patients with LF abnormalities.

References

Apr 1, 1996·Journal of Pharmacokinetics and Biopharmaceutics·R BrunoL B Sheiner
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R BrunoL B Sheiner
Apr 9, 1999·Computer Methods and Programs in Biomedicine·E N Jonsson, M O Karlsson
Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N YamamotoN Saijo
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Boon-Cher GohHow-Sung Lee
Dec 18, 2003·British Journal of Clinical Pharmacology·Kellie A SlavieroLaurent P Rivory
May 11, 2004·Cancer Chemotherapy and Pharmacology·Florent PuissetHenri Roché
Jul 13, 2004·Analytical Biochemistry·Milin R AcharyaAlex Sparreboom
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hironobu MinamiHiroyasu Ogata
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sharyn D BakerAlex Sparreboom
Feb 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albert J ten TijeSharyn D Baker
Mar 3, 2006·Clinical Pharmacokinetics·Sharyn D BakerJaap Verweij

❮ Previous
Next ❯

Citations

Feb 26, 2011·Breast Cancer Research and Treatment·Roisin M ConnollyAntonio C Wolff
Mar 4, 2011·The AAPS Journal·Jurgen Bernd BulittaCornelia Barbara Landersdorfer
May 28, 2011·Journal of Pharmaceutical Sciences·Erika SugiyamaHitoshi Sato
May 28, 2016·Expert Opinion on Drug Safety·Bruno VincenziGiuseppe Tonini
Jun 23, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ting-Yao WangChang-Hsien Lu
Sep 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ryan M FrankeAlex Sparreboom
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph GligorovJean-François Bernaudin
Jan 10, 2017·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Jie WangYu Yu
Apr 28, 2018·Critical Reviews in Analytical Chemistry·Gilmar Hanck da SilvaMarlus Chorilli
Sep 16, 2010·Fundamental & Clinical Pharmacology·Pauline Gerritsen-van SchieveenUNKNOWN Therapeutic drug monitoring group of the French Society of Pharmacology and Therapeutics
Sep 20, 2012·Clinical Pharmacology and Therapeutics·C S LancasterA Sparreboom
Jul 23, 2013·Clinical Pharmacokinetics·Frans L OpdamHenk-Jan Guchelaar
Jan 1, 2014·Journal of Clinical Pharmacology·Chenguang WangCatherijne A J Knibbe
Nov 17, 2019·Pharmaceutical Research·Marie-Rose B S CrombagAlwin D R Huitema
Mar 28, 2013·Journal of Pharmacokinetics and Pharmacodynamics·Emily Colby, Eric Bair
Feb 5, 2015·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Rui HeJinguang Ruan
Apr 1, 2011·Clinical Pharmacology and Therapeutics·R M FrankeA Sparreboom
Jun 24, 2017·British Journal of Clinical Pharmacology·Hirotsugu KenmotsuYusuke Tanigawara
Jan 14, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jessica M van der BolFloris A de Jong
Jan 13, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Frederike K EngelsRon A A Mathot
Nov 16, 2016·ESMO Open·Matthias PinterWolfgang Sieghart

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.